The Firm recently represented the underwriters, led by Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, in connection with the public offering by Boston Scientific Corporation (“Boston Scientific”) of $1.7 billion of debt securities, consisting of $500 million of 1.9% Senior Notes due 2025 and $1.2 billion of 2.65% Senior Notes due 2030. Boston Scientific will use the net proceeds to refinance $450 million of borrowings under its revolving credit facility, pay a portion of its pre-payable bank debt, including $750 million under its $1 billion February 2021 term loan and $500 million under its $1.25 billion April 2021 term loan and for related fees, expenses and premiums.
Boston Scientific, as a global medical technology leader for over 40 years, advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
The Simpson Thacher team for the transaction included Roxane Reardon, Ben Massey and Adriana Estor Restrepo (Capital Markets); Jonathan Cantor and Edward Grais (Tax); Lori Lesser and Alysha Sekhon (Intellectual Property); Abram Ellis and Joseph Betteley (Regulatory); Vanessa Burrows (Healthcare); Michael Isby (Environmental); Jeanne Annarumma and Alyssa Ohanian (ECEB); and Jennie Getsin (FINRA/Blue Sky).